BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 37284891)

  • 1. Evaluation of the anticancer effect of telomerase inhibitor BIBR1532 in anaplastic thyroid cancer in terms of apoptosis, migration and cell cycle.
    Turkmen E; Sogutlu F; Erdogan M; Biray Avci C
    Med Oncol; 2023 Jun; 40(7):196. PubMed ID: 37284891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of telomerase inhibitor on epigenetic chromatin modification enzymes in malignancies.
    Biray Avci C; Dogan F; Ozates Ay NP; Goker Bagca B; Abbaszadeh Z; Gunduz C
    J Cell Biochem; 2018 Dec; 119(12):9817-9824. PubMed ID: 30145821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The efficacy of HRAS and CDK4/6 inhibitors in anaplastic thyroid cancer cell lines.
    Lopes-Ventura S; Pojo M; Matias AT; Moura MM; Marques IJ; Leite V; Cavaco BM
    J Endocrinol Invest; 2019 May; 42(5):527-540. PubMed ID: 30191474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Torin2 targets dysregulated pathways in anaplastic thyroid cancer and inhibits tumor growth and metastasis.
    Sadowski SM; Boufraqech M; Zhang L; Mehta A; Kapur P; Zhang Y; Li Z; Shen M; Kebebew E
    Oncotarget; 2015 Jul; 6(20):18038-49. PubMed ID: 25945839
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transcript-level regulation of MALAT1-mediated cell cycle and apoptosis genes using dual MEK/Aurora kinase inhibitor "BI-847325" on anaplastic thyroid carcinoma.
    Samimi H; Haghpanah V; Irani S; Arefian E; Sohi AN; Fallah P; Soleimani M
    Daru; 2019 Jun; 27(1):1-7. PubMed ID: 31077090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Down-Regulation of the Mammalian Target of Rapamycin (mTOR) Pathway Mediates the Effects of the Paeonol-Platinum(II) Complex in Human Thyroid Carcinoma Cells and Mouse SW1736 Tumor Xenografts.
    He L; Guo S; Zhu T; Chen C; Xu K
    Med Sci Monit; 2020 Jun; 26():e922561. PubMed ID: 32594094
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of Krüppel-Like Factor 4 in the Maintenance of Chemoresistance of Anaplastic Thyroid Cancer.
    Lee SI; Kim DK; Seo EJ; Choi EJ; Kwon YW; Jang IH; Lee JC; Kim HY; Shong M; Kim JH; Kim SJ
    Thyroid; 2017 Nov; 27(11):1424-1432. PubMed ID: 28920531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Small interfering RNA (siRNA) against Slug induces apoptosis and sensitizes human anaplastic thyroid carcinoma cells to doxorubicin.
    Pan Y; Liu P; Chen D; Dou L
    Cancer Biomark; 2017; 18(4):357-366. PubMed ID: 28128736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor effects of proteasome inhibition in anaplastic thyroid carcinoma.
    Altmann A; Markert A; Askoxylakis V; Schöning T; Jesenofsky R; Eisenhut M; Haberkorn U
    J Nucl Med; 2012 Nov; 53(11):1764-71. PubMed ID: 23055533
    [TBL] [Abstract][Full Text] [Related]  

  • 10. S100A4 Knockout Sensitizes Anaplastic Thyroid Carcinoma Cells Harboring BRAFV600E/Mt to Vemurafenib.
    Jiao X; Zhang H; Xu X; Yu Y; Zhang H; Zhang J; Ning L; Hao F; Liu X; Niu M; Chen CT; Chen D; Zhang K
    Cell Physiol Biochem; 2018; 49(3):1143-1162. PubMed ID: 30196299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of Abemaciclib on cell cycle and apoptosis regulation in anaplastic thyroid cancer cells.
    Abutorabi ES; Poursheikhani A; Kashani B; Shamsaiegahkani S; Haghpanah V; Bashash D; Mousavi SA; Momeny M; Ghaffari SH
    Mol Biol Rep; 2023 May; 50(5):4073-4082. PubMed ID: 36877344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel therapeutic approach for anaplastic thyroid cancer through inhibition of LAT1.
    Enomoto K; Sato F; Tamagawa S; Gunduz M; Onoda N; Uchino S; Muragaki Y; Hotomi M
    Sci Rep; 2019 Oct; 9(1):14616. PubMed ID: 31601917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myricetin Induces Apoptosis of Human Anaplastic Thyroid Cancer Cells
    Jo S; Ha TK; Han SH; Kim ME; Jung I; Lee HW; Bae SK; Lee JS
    Anticancer Res; 2017 Apr; 37(4):1705-1710. PubMed ID: 28373432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Flavopiridol causes cell cycle inhibition and demonstrates anti-cancer activity in anaplastic thyroid cancer models.
    Pinto N; Prokopec SD; Ghasemi F; Meens J; Ruicci KM; Khan IM; Mundi N; Patel K; Han MW; Yoo J; Fung K; MacNeil D; Mymryk JS; Datti A; Barrett JW; Boutros PC; Ailles L; Nichols AC
    PLoS One; 2020; 15(9):e0239315. PubMed ID: 32970704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of nutraceuticals on anaplastic thyroid cancer cells.
    Allegri L; Rosignolo F; Mio C; Filetti S; Baldan F; Damante G
    J Cancer Res Clin Oncol; 2018 Feb; 144(2):285-294. PubMed ID: 29197967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel combination of withaferin A and sorafenib shows synergistic efficacy against both papillary and anaplastic thyroid cancers.
    Cohen SM; Mukerji R; Timmermann BN; Samadi AK; Cohen MS
    Am J Surg; 2012 Dec; 204(6):895-900; discussion 900-1. PubMed ID: 23231932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Xiaoaiping combined with cisplatin can inhibit proliferation and invasion and induce cell cycle arrest and apoptosis in human ovarian cancer cell lines.
    Zheng AW; Chen YQ; Fang J; Zhang YL; Jia DD
    Biomed Pharmacother; 2017 May; 89():1172-1177. PubMed ID: 28320083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The novel histone deacetylase inhibitor thailandepsin A inhibits anaplastic thyroid cancer growth.
    Weinlander E; Somnay Y; Harrison AD; Wang C; Cheng YQ; Jaskula-Sztul R; Yu XM; Chen H
    J Surg Res; 2014 Jul; 190(1):191-7. PubMed ID: 24679699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Melatonin synergizes BRAF-targeting agent dabrafenib for the treatment of anaplastic thyroid cancer by inhibiting AKT/hTERT signalling.
    Liao Y; Gao Y; Chang A; Li Z; Wang H; Cao J; Gu W; Tang R
    J Cell Mol Med; 2020 Oct; 24(20):12119-12130. PubMed ID: 32935463
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BET bromodomain inhibitor JQ1 modulates microRNA expression in thyroid cancer cells.
    Mio C; Conzatti K; Baldan F; Allegri L; Sponziello M; Rosignolo F; Russo D; Filetti S; Damante G
    Oncol Rep; 2018 Feb; 39(2):582-588. PubMed ID: 29251329
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.